INFLUENCE OF ETHYLMETHYLHYDROXYPYRIDINE SUCCINATE INCLUSION IN ANTIHYPERTENSIVE THERAPY ON THE CONDITION OF THE ARTERIAL WALL IN YOUNG PATIENTS WITH HYPERTENSION

Authors:

Abstract:

The purpose of the study was to evaluate the impact of combined antihypertensive therapy including ethylmethylhydroxypyridine succinate on blood pressure levels, arterial stiffness and quality of life in young patients with hypertension. A total of 60 patients (mean age, 41.7±1.3 years) with grade 2 hypertension who were not taking regular antihypertensive therapy were examined. After baseline data collection, 30 patients (group 1) were administered basic therapy with antihypertensive drugs and ethylmethylhydroxypyridine succinate, and 30 patients (group 2) were administered basic therapy, which included a combination of lisinopril 10–20 mg/day and amlodipine 5–10 mg/day for 8 weeks. After the treatment, a decrease in systolic and diastolic blood pressure levels in groups 1 and 2 by 23.3 mm Hg and 17.5 mm Hg and 14.3 mm Hg and 8.4 mm Hg, respectively, was observed (all p<0.05). It was found that average daily levels of systolic and diastolic blood pressure were 7.1 % and 10.8 % (p<0.05) lower in the patients of group 1 compared to group 2 and had a positive effect on daily BP profiles. A more significant decrease in the pulse wave velocity in the aorta was observed (2.1±0.5 m/s, p<0.05) in group 1, while in group 2 this parameter decreased by (1.5±0.5 m/s, p<0.05). There was an improvement in the scale scores representing physical health, working capacity, psychological abilities, degree of severity of negative psychological state, as well as the ability to social contacts more expressed in group 1. Therefore, inclusion of ethylmethylhydroxypyridine succinate in the therapeutic complex in young patients with hypertension increases efficacy of antihypertensive therapy, improves daily blood pressure profiles and positively affects the quality of life in this category of patients.

Keywords:

hypertension young age combined antihypertensive therapy ethylmethylhydroxypyridine succinate arterial stiffness quality of life

References:

1. Dolzhenko M, Popovich O, Shershnyova O, Nudchenko O, Faradzh K, Djachenko Y, et al. Zastosuvannya etylmetylhidroksypirydynu u khvorykh z infarktom miokarda: antyishemichnyy, antydepresyvnyy, transportnyy efekty. Family Medicine. 2016; 4: 67–74. doi.org/10.30841/2307-5112.4.2016.248524 [in Ukrainian]
2. Katerenchuk IP, Mokhnachov OV. Komplaiens yak peredumova efektyvnosti terapii komorbidnoho perebihu hipertonichnoi khvoroby. Visnyk problem biolohii i medytsyny. 2019; 2(2):120–123 [in Ukrainian].
3. Lutsenko RV. Antyoksydantna diia pokhidnoho 2-oksoindolin-3-hlioksylovoi kysloty za eksperymentalnoi patolohii sertsia ta nyrok. Farmakolohiia ta likarska toksykolohiia. 2022; 16 (6):381–386 [in Ukrainian].
4. Mishchenko LA, Ovdiienko TM, Matova OO, Talaieva TV, Tretiak IV, Vasylynchuk NM, et al. Funktsionalnyi stan endoteliiu ta dodatkovi mozhlyvosti yoho korektsii pry zastosuvanni etylmetylhidroksypirydynu suktsynatu u patsiientiv iz arterialnoiu hipertenziieiu. Uk. Med.zh.. 2021;486 doi: 10.32471/umj.1680-3051.144.213876 [in Ukrainian]
5. Bronze L. War, hypertension and post traumatic stress disorder. A personal experience, Blood Pressure, 2022; 31(1): 225–227, doi: 10.1080/08037051.2022.2118661.[
6. Carey RM, Wright JT, Taler SJ, Whelton PK. Guideline-Driven Management of Hypertension: An Evidence-Based Update. Circ Res. 2021; 128(7):827–846. doi: 10.1161/CIRCRESAHA.121.318083.
7. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021; 398(10304): 957–980. doi: 10.1016/S0140-6736(21)01330-1.
8. Nevoit GV, Korpan AS, Кіtura OE, Nastroga TV, Sokolyuk NL, Lyulka N.A. et al. Electro-photonic emission analysis in patients with noncommunicable diseases: essential hypertension World of Medicine and Biology. 2023;1(83): 138–143. doi: 10.26724/2079-8334-2023-1-83-138-143
9. Nour Eldine M, Alhousseini M, Nour-Eldine W, Noureldine H, Vakharia KV, Krafft PR, Noureldine MHA. The Role of Oxidative Stress in the Progression of Secondary Brain Injury Following Germinal Matrix Hemorrhage. Transl Stroke Res. 2023; Mar 17. doi: 10.1007/s12975-023-01147-3.
10. Truong Sinh C, Ngoc Linh H. Effects of lisinopril and amlodipin in combination for the treatment of hypertension with pulse wave velocity vp plus 1000 meter. Vietnam medicak journal. 2022; 515(1). https://doi.org/10.51298/vmj.v515i1.2421
11. WHO, World Health Organization, Hypertension Factsheet. http://www.WHO.int.
12. Wu HP, Lin MJ. Central aortic pressure and long-term outcome in hypertensive patients undergoing percutaneous coronary intervention. Sci Rep. 2020 Oct 15;10(1):17420. doi: 10.1038/s41598-020-74619-3.
13. Yuichiro Y. Blood Pressure in Young Adults and Cardiovascular Disease Later in Life, American Journal of Hypertension, 34(3):250–257, https://doi.org/10.1093/ajh/hpab005
14. Yusuf S, Joseph P, Rangarajan S, Islam S, Mente A, Hystad P, et al. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet. 2020 Mar 7;395(10226):795–808. doi: 10.1016/S0140-6736(19)32008-2. Epub 2019 Sep 3. Erratum in: Lancet. 2020 Mar 7;395(10226):784.

Publication:

«World of Medicine and Biology» Vol. 19 No. 85 (2023) , с. 36-41
УДК 616.12-008.331.1-085.225.2-053.81

DOI:

https://doi.org/10.26724/2079-8334-2023-3-85-36-41